Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Total Liabilities (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Total Liabilities data on record, last reported at $26.1 million in Q1 2026.

  • On a quarterly basis, Total Liabilities rose 60.85% to $26.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $26.1 million, a 60.85% increase, with the full-year FY2025 number at $27.8 million, up 192.22% from a year prior.
  • Total Liabilities reached $26.1 million in Q1 2026 per RAPP's latest filing, down from $27.8 million in the prior quarter.
  • Over the last five years, Total Liabilities for RAPP hit a ceiling of $39.6 million in Q1 2024 and a floor of $8.0 million in Q3 2024.
  • A 4-year average of $18.3 million and a median of $15.3 million in 2023 define the central range for Total Liabilities.
  • On a YoY basis, Total Liabilities climbed as much as 195.22% in 2025 and fell as far as 59.08% in 2025.
  • Tracing RAPP's Total Liabilities over 4 years: stood at $14.5 million in 2023, then crashed by 34.35% to $9.5 million in 2024, then soared by 192.22% to $27.8 million in 2025, then dropped by 6.09% to $26.1 million in 2026.
  • Business Quant data shows Total Liabilities for RAPP at $26.1 million in Q1 2026, $27.8 million in Q4 2025, and $23.7 million in Q3 2025.